BHCM
FHTX icon

Brevan Howard Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Brevan Howard Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,486
Closed -$56.6K – 2252
2025
Q4 		$56.6K Buy
+10,486
New +$47.5K ﹤0.01% 1697
2025
Q2 		– Sell
-28,606
Closed -$104K – 1895
2025
Q1 		$104K Buy
+28,606
New +$130K ﹤0.01% 1048

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Brevan Howard Capital Management's FHTX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Foghorn Therapeutics (FHTX) in Q1 2026, closing a stake of 10,486 shares — an estimated $56.6K sold.

Brevan Howard Capital Management first reported a position in FHTX in Q1 2025 and held it in 2 quarters. The position peaked at $104K in Q1 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Foghorn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,486 Foghorn Therapeutics shares in Q1 2026, an estimated $56.6K.
  • Brevan Howard Capital Management first reported a position in Foghorn Therapeutics in Q1 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Foghorn Therapeutics position peaked at $104K in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.